相关实验视频

Updated: May 5, 2026

Non-invasive Assessment of Microvascular and Endothelial Function

Non-invasive Assessment of Microvascular and Endothelial Function

Published on: January 29, 2013

在高血压患者内源性内甲素-1的血管收缩活性中的种族差异

Umberto Campia¹, Carmine Cardillo, Julio A Panza

¹National Heart, Lung, and Blood Institute, Bethesda, Md, USA.

|May 19, 2004

概括

黑人高血压患者表现出较高的内甲素-1 (ET-1) 活性,导致血管收缩增加. 这表明ET-1在黑人高血压病原体中的关键作用.

科学领域:

心血管研究研究心血管研究
高血压病理生理学高血压病理生理学
种族健康差异的差异

背景情况:

基本高血压的发病因子可能在黑人和白人之间有所不同.
黑人患者经常出现盐敏感,低蛋白高血压,可能与增强的内甲蛋白-1 (ET-1) 活性有关.
这项研究研究了在正常血压和高血压个体的血管ET-1活性中的种族差异.

研究的目的:

为了确定血管内甲蛋白-1 (ET-1) 活性是否存在种族差异.
评估ET-1在高血压黑白患者的血管度中的作用.

主要方法:

使用充血镜分析了前臂血流 (FBF) 对静脉内输注ET(A) 受体阻塞剂 (BQ-123) 的反应.
参与者包括正常血压和高血压的黑白患者.
还评估了对外源ET-1的血管反应,以评估光滑肌肉的反应性.

主要成果:

ET(A) 受体阻塞在高血压患者中引起显著的血管扩张,但在正常血压患者中没有.
在高血压的黑人患者中,ET(A) 受体阻塞的血管扩张作用明显大于高血压的白人患者.
外源ET-1在高血压的黑人和白人患者中诱导了类似的血管收缩,这表明光滑肌肉反应性没有差异.

结论:

高血压的黑人个体表现出增强的依赖ET(A) 的血管缩体调,可能是由于ET-1的产量增加.
这种提升的ET-1活性可能导致黑人患者高血压的发病和并发症.

更多相关视频

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

相关概念视频

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...